Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
The GPS result and percent positive cores appear associated with AS use after controlling for relevant clinical variables in NCCN FIR prostate cancer patients.
Authors
- João Paulo Zambon
- John P. Bennett (ORCID: https://orcid.org/0000-0001-5184-7912)
- Christopher Pieczonka (ORCID: https://orcid.org/0000-0002-2531-7587)
- Benjamin Lowentritt (ORCID: https://orcid.org/0000-0002-2921-6249)
- Edward Uchio
- Jack Groskopf (ORCID: https://orcid.org/0000-0003-4932-8608)
- M. B. Pavlova (ORCID: https://orcid.org/0000-0002-3674-906X)
- Eric Margolis
Institutions
- Exact Sciences (United States) (US)
- IDEX Corporation (United States) (US)
- Chesapeake Urology Associates (US)
- Center for Discovery (US)
Publication Details
- Journal
- BJUI Compass
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/bco2.494
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00